Related Experiment Video
Updated: Jun 9, 2025
06:50
Extraction and Analysis of Taiwanese Green Propolis
Published on: January 7, 2019
8.4K
Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes
Oana C Iatcu1, Sevag Hamamah2,3, Mihai Covasa1,2
1Department of Biomedical Sciences, College of Medicine and Biological Science, University of Suceava, 720229 Suceava, Romania.
Nutrients
|October 26, 2024
Summary
Prebiotics can improve gut microbiota balance and glycemic control in type 2 diabetes mellitus (T2DM). Optimizing gut bacteria through prebiotics may help manage T2DM and reduce complications.
Area of Science:
- Microbiology
- Metabolic Health
- Nutritional Science
Background:
- The gut microbiota significantly influences metabolic health and disease susceptibility.
- Gut dysbiosis is linked to type 2 diabetes mellitus (T2DM) development via impaired glucose tolerance and insulin resistance.
- Eubiosis, a balanced gut microbiota, promotes glucose metabolism and insulin sensitivity, potentially mitigating diabetes complications.
Purpose of the Study:
- To review the effects of various prebiotics on T2DM.
- To examine the impact of prebiotics on gut microbiota composition in T2DM patients.
- To explore personalized dietary interventions for optimizing T2DM management.
Main Methods:
- Literature review of studies on prebiotics and T2DM.
- Analysis of changes in gut microbial composition associated with T2DM and prebiotic intervention.
- Evaluation of glycemic control and insulin sensitivity markers.
Main Results:
- T2DM is associated with reduced beneficial bacteria (e.g., Roseburia, Faecalibacterium) and increased harmful bacteria (e.g., Escherichia, Prevotella).
- Prebiotics (inulin, FOS, GOS, resistant starch, polyphenols, β-glucan, Dendrobium officinale) improve gut microbial balance.
- Prebiotic intake supports glycemic control and enhances beneficial bacteria in T2DM patients.
Conclusions:
- Prebiotics demonstrate potential in modulating gut microbiota for improved glycemic control in T2DM.
- Targeting gut microbiota with prebiotics offers a promising avenue for personalized diabetes management.
- Further research into personalized prebiotic interventions can enhance T2DM outcomes and overall health.
More Related Videos
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:36Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:15Diabetes: Management and Pharmacotherapy
237
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
237
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K